Subscribe to our Newsletters !!
A lion or eagle may come to mind when considering
In science, the interference of materials, reagent
Dr. Mohammed Enayat’s recent testimony on his ag
This year, the Hamburg based life sciences company
Unlike other medications, Vyvanse (Lisdexamfetamin
Since it’s an ingredient in so many foods, you h
In our cover story, we shine a spotlight on “ The Magazine
The company has received approval from the United States Food and Drug Administration (USFDA) to advertise its own Dimethyl Fumarate delayed-release capsules in the strengths of 120 mg and 240 mg, Lupin said in a statement.
The item is a generic version of Biogen Inc”s Tecfidera delayed-release capsules at the same strengths, it added.
The company hopes to launch the product shortly, the announcement said.
According to the IQVIA MAT June 2020 data, Dimethyl Fumarate delayed-release capsules had an annual sales of approximately USD 3,788 million in the US, Lupin said.
The capsules are suggested,”for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and lively secondary progressive disease, in adults,” it added.
PTI AKT RUJ RUJ
